![Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib]()
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibShah, N. P.; Kim, D.-W.; Kantarjian, H.; Rousselot, P.; Llacer, P. E. D.; Enrico, A.; Vela-Ojeda, J.; Silver, R. T.; Khoury, H. J.; Muller, M. C.; Lambert, A.; Matloub, Y.; Hochhaus, A. · Haematologica · 2010